Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT PK Interaction with Lithium, Valproic Acid, and Lamotrigine
NCT06729970Phase 1Completed
- Sponsor
- Karuna Therapeutics
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started Dec 2024; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06729970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06729970.